KAIYUAN SECURITIES·2026-01-29 07:25Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]